Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Details : MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.
Brand Name : MK-0616
Molecule Type : Peptide
Upfront Cash : Not Applicable
August 25, 2023
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.
Brand Name : MK-0616
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 06, 2023
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MK-0616 is an investigational macrocyclic peptide that binds to PCSK9 and inhibits the interaction of PCSK9 with LDL receptors resulting in greater numbers of LDL receptors available on the cell surface to remove LDL cholesterol from the blood.
Brand Name : MK-0616
Molecule Type : Peptide
Upfront Cash : Not Applicable
February 21, 2023
Lead Product(s) : MK-0616
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?